Lorenzo De Paoli

Lorenzo De Paoli

Auto-generated profile, based on publicly available information

Lorenzo De Paoli

Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2012 in Blood
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
SRSilvia Rasi
Silvia Rasi
GFGiulia Fabbri
Giulia Fabbri
VSValeria Spina
Valeria Spina
MFMarco Fangazio
Marco Fangazio
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.

3 April 2014 in Blood
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
HKHossein Khiabanian
Hossein Khiabanian
VSValeria Spina
Valeria Spina
CCCarmela Ciardullo
Carmela Ciardullo
ABAlessio Bruscaggin
Alessio Bruscaggin
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Key Points: Small TP53 mutated subclones have the same unfavorable prognostic impact as clonal TP53 defects in chronic lymphocytic leukemia.

1 February 2009 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
MCMichaela Cerri
Michaela Cerri
CDClara Deambrogi
Clara Deambrogi
ESElisa Sozzi
Elisa Sozzi
SCStefania Cresta
Stefania Cresta
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Purpose: Del17p13 predicts poor outcome and chemorefractoriness in chronic lymphocytic leukemia (CLL). Conversely, it is unknown whether TP53 mutations carry any prognostic value independent of del17p13. We tested the independent prognostic value of TP53 mutations in CLL. Experimental Design: The study was based on a consecutive series of 308 CLL. DNA sequencing of TP53 exons 2 to 10 and del17p13 interphase fluorescence in situ hybridization were done at CLL diagnosis. Study end points were survival and chemorefractoriness. Results: At diagnosis, TP53 mutations (n = 32) occurred in 31 of 308 (10.0%) patients. Of all CLL showing TP53 disruption by either mutation and/or deletion (n = 44), 10 cases (22.7%) showed TP53 mutations in the absence of del17p13. Multivariate analysis selected TP53 mutations (hazard ratio, 3.20; P = 0.002) as an independent predictor of overall survival after adjustment for del17p13. Also, multivariate analysis selected TP53 mutations (hazard ratio, 3.97; P < 0.001) as an independent predictor of chemorefractoriness after adjustment for del17p13. Compared with cases without TP53 alterations, CLL harboring any type of TP53 disruption (mutation only, del17p13 only, or both mutation and del17p13) uniformly displayed a high prevalence of unfavorable prognosticators and poor outcome. Analysis of sequential CLL samples showed the acquisition of new or additional TP53 alterations at the time of chemorefractoriness. Conclusions: These data show that (a) TP53 mutations are an independent predictor of short survival and chemorefractoriness, and (b) that CLL presenting with TP53 mutations without del17p13 fare as poorly as CLL carrying del17p13. Because CLL harboring TP53 mutations without del17p13 are currently not recognized by conventional diagnostic strategies, these results may be relevant for a comprehensive prognostic characterization of CLL.

28 June 2008 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
DRDavide Rossi
Davide Rossi
MCMichaela Cerri
Michaela Cerri
Daniela CapelloDaniela Capello
Daniela Capello
CDClara Deambrogi
Clara Deambrogi
FRFrancesca Maria Rossi
Francesca Maria Rossi
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano

1 July 2009 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
VSValeria Spina
Valeria Spina
MCMichaela Cerri
Michaela Cerri
SRSilvia Rasi
Silvia Rasi
CDClara Deambrogi
Clara Deambrogi
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Purpose: Few biological prognosticators are useful for prediction of Richter syndrome (RS), representing the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. Stereotyped B-cell receptors (BCR) may have prognostic effect in CLL progression. We tested the prognostic effect of stereotyped BCR for predicting RS transformation. Experimental Design: The prevalence of stereotyped BCR was compared in RS (n = 69) versus nontransformed CLL (n = 714) by a case-control analysis. Subsequently, the effect of stereotyped BCR at CLL diagnosis on risk of RS transformation was actuarially assessed in a consecutive CLL series (n = 753). Results: RS (n = 69) displayed a higher prevalence of stereotyped BCR (P < 0.001) compared with nontransformed CLL. The actuarial risk of RS transformation was significantly higher in CLL carrying stereotyped BCR (P < 0.001). Among BCR subsets most represented in CLL, subset 8 using IGHV4-39/IGHD6-13/IGHJ5 carried the highest risk of RS transformation [hazard ratio (HR), 24.50; P < 0.001]. Multivariate analysis selected stereotyped BCR (HR, 3.33; P = 0.001) and IGHV4-39 usage (HR, 4.03; P = 0.004) as independent predictors of RS transformation. The combination of IGHV4-39 usage and stereotyped BCR in the same patient identified CLL with a very high risk of RS transformation (5-year risk, 68.7%). The risk carried by stereotyped BCR and IGHV4-39 usage was specific for RS transformation and had no effect on CLL progression without transformation. Conclusions: Analysis of BCR features may help identify CLL patients at risk of RS. A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.

15 October 2015 in Blood
Verified
Journal Article
Open access
PDF file
DRDavide Rossi
Davide Rossi
LTLodovico Terzi-Di-Bergamo
Lodovico Terzi-Di-Bergamo
LPLorenzo De Paoli
Lorenzo De Paoli
MCMichaela Cerri
Michaela Cerri
GGGuido Ghilardi
Guido Ghilardi
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Key Points: CLL patients harboring mutated IGHV genes but neither 11q or 17p deletion experience durable remission after frontline FCR.